Wegovy users have less kidney-related health problems, analysis of Novo study finds By Reuters Stocks May 25, 2024 By Maggie Fick LONDON (Reuters) – Novo Nordisk (NYSE:)’s Wegovy obesity drug reduced adverse kidney-related events by 22% in overweight…